Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to...
All the resolutions proposed by the Board of Directors were adopted Paris and Boston, June 7, 2024 - 8:00 a.m. CEST - Mauna Kea Technologies...
JV now operational to start selling products in China Paris and Boston, June 6, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies...
Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award Prestigious...
Paris and Boston, May 21, 2024 - 5:45 p.m. CEST - Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology’s largest international...
Paris and Boston, April 30, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Cellvizio utilization continues to expand globally in established and emerging clinical indications Paris and Boston, April 29, 2024 –...
Full Year 2023 Sales increased +42%1 to €10.5m €1.2m positive full-year operating income +47% growth in Q1 2024 in U.S PPU...
Renewed EIB confidence in Mauna Kea extending support until 2029 Final maturities deferred 4 years to 2028 and 2029 Alignment of debt...
Italy becomes the third country to launch a Cellvizio Center of Excellence following the Metrodora Institute in the U.S. and several other centers...
Paris, Boston, and London, March 27, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
